They also differentiated the innovator biologic Semaglutide molecule from newer synthetic or chemical generic versions entering the market
Phase I to supply clean energy to five facilities, with long-term plans to power 19 hospitals through a 30 MW renewable network
Board approves five-year appointment, subject to shareholder nod through postal ballot
Paid-up equity capital rises to Rs 973.19 crore following allotment to eligible employees
Wholly owned subsidiary KIMS Swastha signs hospital management and sub-lease deal for 210-bed facility, with option to acquire majority stake later
Minister highlights scope for domestic manufacturing during his meeting with Dr Niti Pall, President-elect, International Diabetes Federation
Institute signs four MoUs, launches two products and marks 75 years with renewed focus on lab-to-market commercialisation
Rs 66 lakh acquisition will support DNA engineering and novel cell-gene therapy alternatives to conventional chemotherapy
The company has highlighted setbacks in Phase II studies while outlining fresh regulatory and late-stage development plans for Fibromun and Nidlegy
Parliament clears reform bill replacing jail terms for procedural lapses with graded monetary penalties across key health laws
Subscribe To Our Newsletter & Stay Updated
